For the quarter ending 2025-09-30, CLSD made $201,000 in revenue. -$5,972,000 in net income. Net profit margin of -2971.14%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| License and other revenue (includes 171 and 81 from a related party for the three months ended september 30, 2025 and 2024, respectively, and 655and 237 for the nine months ended september 30, 2025 and 2024, respectively) | 201,000 | 492,000 | 2,330,000 | 208,666.667 |
| Cost of goods sold | 0 | 0 | 248,000 | 37,250 |
| Research and development (includes 255 and 473 to a related party for the three and nine months ended september 30, 2024, respectively) | 2,933,000 | 1,584,000 | 4,463,000 | 4,820,666.667 |
| General and administrative | 4,308,000 | 2,476,000 | 2,824,000 | 2,987,666.667 |
| Total operating expenses | 7,241,000 | 4,060,000 | 7,535,000 | 7,858,000 |
| Loss from operations | -7,040,000 | -3,568,000 | -5,205,000 | -7,649,333.333 |
| Other income, net | - | - | - | 827,333.333 |
| Interest income | 65,000 | 115,000 | 163,000 | 374,666.667 |
| Other income, net | 3,573,000 | 1,720,000 | 207,000 | - |
| Non-cash interest expense on liability related to the sales of future royalties | 2,570,000 | 2,762,000 | 2,673,000 | 2,440,666.667 |
| Loss before income taxes | -5,972,000 | -4,495,000 | -7,508,000 | - |
| Income tax expense | 0 | 0 | 715,000 | - |
| Net loss | -5,972,000 | -4,495,000 | -8,223,000 | -8,888,000 |
| Net loss per share of common stock - basic | -1.14 | -0.06 | -0.11 | -0.123 |
| Net loss per share of common stock - diluted | -1.14 | -0.06 | -0.11 | -0.123 |
| Weighted average shares outstanding - basic | 5,233,981 | 77,844,055 | 76,921,843 | -314,022.333 |
| Weighted average shares outstanding - diluted | 5,233,981 | 77,844,055 | 76,921,843 | -314,022.333 |
Clearside Biomedical, Inc. (CLSD)
Clearside Biomedical, Inc. (CLSD)